KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Treasury Shares (2017 - 2026)

Twist Bioscience has reported Treasury Shares over the past 10 years, most recently at $2.8 million for Q1 2026.

  • Quarterly Treasury Shares rose 35.16% to $2.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Mar 2026, up 35.16% year-over-year, with the annual reading at $1.9 million for FY2025, 61.41% up from the prior year.
  • Treasury Shares was $2.8 million for Q1 2026 at Twist Bioscience, down from $3.0 million in the prior quarter.
  • Over five years, Treasury Shares peaked at $3.0 million in Q4 2025 and troughed at $700000.0 in Q2 2023.
  • The 5-year median for Treasury Shares is $1.4 million (2023), against an average of $1.6 million.
  • Year-over-year, Treasury Shares skyrocketed 172902.75% in 2022 and then plummeted 44.27% in 2023.
  • A 5-year view of Treasury Shares shows it stood at $759000.0 in 2022, then skyrocketed by 85.11% to $1.4 million in 2023, then skyrocketed by 46.83% to $2.1 million in 2024, then soared by 46.0% to $3.0 million in 2025, then decreased by 5.81% to $2.8 million in 2026.
  • Per Business Quant, the three most recent readings for TWST's Treasury Shares are $2.8 million (Q1 2026), $3.0 million (Q4 2025), and $1.9 million (Q3 2025).